278 related articles for article (PubMed ID: 20041668)
1. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
2. Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution.
Saunders LP; Cao W; Chang WC; Albright RA; Braddock DT; De La Cruz EM
J Biol Chem; 2011 Aug; 286(34):30130-41. PubMed ID: 21719699
[TBL] [Abstract][Full Text] [Related]
3. Characterization of non-lipid autotaxin inhibitors.
Hoeglund AB; Howard AL; Wanjala IW; Pham TC; Parrill AL; Baker DL
Bioorg Med Chem; 2010 Jan; 18(2):769-76. PubMed ID: 20005724
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs.
North EJ; Osborne DA; Bridson PK; Baker DL; Parrill AL
Bioorg Med Chem; 2009 May; 17(9):3433-42. PubMed ID: 19345587
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of boronic acid based inhibitors of autotaxin.
Albers HM; van Meeteren LA; Egan DA; van Tilburg EW; Moolenaar WH; Ovaa H
J Med Chem; 2010 Jul; 53(13):4958-67. PubMed ID: 20536182
[TBL] [Abstract][Full Text] [Related]
6. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
North EJ; Howard AL; Wanjala IW; Pham TC; Baker DL; Parrill AL
J Med Chem; 2010 Apr; 53(8):3095-105. PubMed ID: 20349977
[TBL] [Abstract][Full Text] [Related]
8. Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors.
Tabchy A; Tigyi G; Mills GB
Nat Struct Mol Biol; 2011 Feb; 18(2):117-8. PubMed ID: 21289650
[TBL] [Abstract][Full Text] [Related]
9. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.
Albers HM; Dong A; van Meeteren LA; Egan DA; Sunkara M; van Tilburg EW; Schuurman K; van Tellingen O; Morris AJ; Smyth SS; Moolenaar WH; Ovaa H
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7257-62. PubMed ID: 20360563
[TBL] [Abstract][Full Text] [Related]
10. Regulation and biological activities of the autotaxin-LPA axis.
van Meeteren LA; Moolenaar WH
Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid.
Tanaka M; Okudaira S; Kishi Y; Ohkawa R; Iseki S; Ota M; Noji S; Yatomi Y; Aoki J; Arai H
J Biol Chem; 2006 Sep; 281(35):25822-30. PubMed ID: 16829511
[TBL] [Abstract][Full Text] [Related]
12. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.
van Meeteren LA; Ruurs P; Stortelers C; Bouwman P; van Rooijen MA; Pradère JP; Pettit TR; Wakelam MJ; Saulnier-Blache JS; Mummery CL; Moolenaar WH; Jonkers J
Mol Cell Biol; 2006 Jul; 26(13):5015-22. PubMed ID: 16782887
[TBL] [Abstract][Full Text] [Related]
13. ATX-LPA axis induces expression of OPN in hepatic cancer cell SMMC7721.
Zhang R; Zhang Z; Pan X; Huang X; Huang Z; Zhang G
Anat Rec (Hoboken); 2011 Mar; 294(3):406-11. PubMed ID: 21337710
[TBL] [Abstract][Full Text] [Related]
14. Cyclic phosphatidic acid is produced by autotaxin in blood.
Tsuda S; Okudaira S; Moriya-Ito K; Shimamoto C; Tanaka M; Aoki J; Arai H; Murakami-Murofushi K; Kobayashi T
J Biol Chem; 2006 Sep; 281(36):26081-8. PubMed ID: 16837466
[TBL] [Abstract][Full Text] [Related]
15. Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.
David M; Wannecq E; Descotes F; Jansen S; Deux B; Ribeiro J; Serre CM; Grès S; Bendriss-Vermare N; Bollen M; Saez S; Aoki J; Saulnier-Blache JS; Clézardin P; Peyruchaud O
PLoS One; 2010 Mar; 5(3):e9741. PubMed ID: 20305819
[TBL] [Abstract][Full Text] [Related]
16. ATX-LPA receptor axis in inflammation and cancer.
Liu S; Murph M; Panupinthu N; Mills GB
Cell Cycle; 2009 Nov; 8(22):3695-701. PubMed ID: 19855166
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions.
Nakasaki T; Tanaka T; Okudaira S; Hirosawa M; Umemoto E; Otani K; Jin S; Bai Z; Hayasaka H; Fukui Y; Aozasa K; Fujita N; Tsuruo T; Ozono K; Aoki J; Miyasaka M
Am J Pathol; 2008 Nov; 173(5):1566-76. PubMed ID: 18818380
[TBL] [Abstract][Full Text] [Related]
18. Autotaxin: a protein with two faces.
Tania M; Khan MA; Zhang H; Li J; Song Y
Biochem Biophys Res Commun; 2010 Oct; 401(4):493-7. PubMed ID: 20888793
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis.
Li S; Wang B; Xu Y; Zhang J
Mol Cancer; 2011 Feb; 10():18. PubMed ID: 21314984
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
van Meeteren LA; Ruurs P; Christodoulou E; Goding JW; Takakusa H; Kikuchi K; Perrakis A; Nagano T; Moolenaar WH
J Biol Chem; 2005 Jun; 280(22):21155-61. PubMed ID: 15769751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]